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Convalescent plasma, widely utilized in viral infections that induce neutralizing antibodies,
has been proposed for COVID-19, and preliminary evidence shows that it might have bene-
ficial effect. Our objective was to determine the risk factors for 28-days mortality in patients
who received convalescent plasma for COVID-19 compared to those who did not, who were
admitted to hospitals in Buenos Aires Province, Argentina, throughout the pandemic.
Methods
This is a multicenter, retrospective cohort study of 2-month duration beginning on June 1,
2020, including unselected, consecutive adult patients with diagnosed COVID-19, admitted
to 215 hospitals with pneumonia. Epidemiological and clinical variables were registered in
the Provincial Hospital Bed Management System. Convalescent plasma was supplied as
part of a centralized, expanded access program.
Results
We analyzed 3,529 patients with pneumonia, predominantly male, aged 62±17, with arterial
hypertension and diabetes as main comorbidities; 51.4% were admitted to the ward, 27.1%
to the Intensive Care Unit (ICU), and 21.7% to the ICU with mechanical ventilation require-
ment (ICU-MV). 28-day mortality was 34.9%; and was 26.3%, 30.1% and 61.4% for ward,
ICU and ICU-MV patients. Convalescent plasma was administered to 868 patients (24.6%);
their 28-day mortality was significantly lower (25.5% vs. 38.0%, p<0.001). No major adverse
effects occurred. Logistic regression analysis identified age, ICU admission with and without
MV requirement, diabetes, and preexistent cardiovascular disease as independent
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predictors of 28-day mortality, whereas convalescent plasma administration acted as a pro-
tective factor.
Conclusions
Our study suggests that the administration of convalescent plasma in COVID-19 pneumonia
admitted to the hospital might be associated with improved outcomes.
Introduction
In December 2019 in Wuhan, China, the first cases of pneumonia caused by SARS-CoV-2, a
novel coronavirus, were reported; the disease was subsequently named COVID-19. The new
virus spread across the world relentlessly, and on March 11 the World Health Organization
declared COVID-19 a pandemic. Up to now, COVID-19 cases are approaching 30,000,000
with 935,000 dead [1, 2].
Few treatments have proven effective for COVID-19 [3]. The administration of conva-
lescent plasma, widely utilized in viral infections that induce neutralizing antibodies, has also
been proposed [4–6]. It was used during outbreaks of severe acute respiratory disease caused
by other coronaviruses, SARS-CoV-1 and MERS-CoV, with varying results and when admin-
istered early, it decreased length of hospital stay [7–9]. Convalescent plasma utilization has an
acceptable safety profile and its administration constitutes a feasible approach to implement
during a pandemic, even in low-resource settings. In COVID-19, it might reduce viral burden,
improve clinical status, and decrease mortality [10–12]. On March 24, 2020, the Food and
Drug Administration of the United States launched an Expanded Access Program to collect
convalescent plasma donated by individuals who had recovered from COVID-19, and on
August 23 approved emergency use [13]. A study conducted in 20,000 patients confirmed the
safety of convalescent plasma and, thereafter, in a study of 30,000 patients, the same group of
researchers demonstrated a decrease in mortality when convalescent plasma was administered
early in the course of COVID-19 [11, 14]. Convalescent plasma is currently being evaluated in
126 clinical trials [15].
Early in the emergency caused by the COVID-19 pandemic, the Ministry of Health of the
Province of Buenos Aires, Argentina, created the Centralized Registry of Convalescent Plasma
Donors (CROCPD-BA), with the aim of collecting, processing and distributing convalescent
plasma, and issuing recommendations for its use in patients with COVID-19 [16]. Accord-
ingly, the objective of the present study was to determine the risk factors for 28-days mortality
in patients who received convalescent plasma for COVID-19 and those who did not, who were
admitted to hospitals in Buenos Aires Province for COVID-19 throughout the pandemic.
Materials and methods
This was a multicenter cohort study conducted over 2 months, beginning on June 1, 2020,
which included consecutive patients�18 years diagnosed with SARS CoV-2 with RT-PCR,
admitted to hospitals with pneumonia. Data were obtained from the National Vigilance Sys-
tem (SNVS 2.0), the Provincial Hospital Bed Management System, and the CROCPD-BA.
Collected variables were age, gender, comorbidities [17, 18] (arterial hypertension, diabetes,
preexistent cardiovascular disease, chronic obstructive pulmonary disease, immunodefi-
ciency), requirement of mechanical ventilation, treatments, death or discharge, and conva-
lescent plasma administration. Severe adverse events related to plasma infusion, as
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transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload
(TACO) were also recorded [19].
Information about plasma collection and characteristics is available in the S1 File.
The requirement of convalescent plasma was initiated by assistant physicians as part of a
Program of Expanded Access [16]. The indications issued by the CROCPD-BA were presence
of pneumonia, defined as of lung infiltrates, plus one of the following:




• Increase in lung infiltrates >50% during the previous 24–48 hours
• Alteration I n consciousness
• Multiple organ dysfunction
• Age>65 years
• Any of the above mentioned comorbidities
All units of transfused convalescent plasma had an Ig-G antibody titer�1:400. Levels of
IgG anti-SARS-Cov2 were tested in all units by means of the test ELISA COVIDAR IgG, (Insti-
tuto Leloir, Argentina). This test utilizes the trimer of native protein S and a receptor binding
domain as antigens, obtained by recombinant DNA techniques produced in human cells. The
infused volume per unit was 200–250 ml.
Initial severity of illness was assessed according to the site of admission: general ward,
Intensive Care Unit (ICU), and ICU admission with requirement of mechanical ventilation
(ICU-VM). The main outcome variable was 28-day mortality. Deaths due to COVID-19 were
confirmed on patient death certificates.
Statistical analysis: Continuous variables were expressed as mean ± standard deviation (SD)
or median, [0.25–0.75] percentiles. Categorical variables were expressed as percentages. Differ-
ences between survivors and nonsurvivors, and between patients who received plasma or not,
were analyzed with chi-square, t, or Mann-Whitney U-tests, as appropriate.
To identify independent predictors of 28-day mortality, variables differing between survi-
vors and nonsurvivors with a p value <0.10 were entered into a multivariable regression
model, using a forward stepwise analysis. The model was constructed in one block with all var-
iables at the same level. Age was introduced as a continuous variable; site of admission as an
ordinal variable using admission at general ward as reference group. Gender, risk factors and
plasma administration were introduced as categorical variables. Adjusted risks were expressed
as odd ratios (OR) and confidence intervals of 95% [CI95%]. A two-tailed p value <0.05 was
considered significant.
Data were analyzed with SSPS-21 (Amonk, NY, US).
This study was approved by the Central Ethics Committee of the Ministry of Health of Bue-
nos Aires Province (Expedient 2020–14965594). The resolution 103/2017 of the Ministry of
Health of the Province of Buenos Aires establishes the obligation of registration and accredita-
tion of all the Institutional Ethics Committees at the Central Ethics Committee of the Ministry
of Health the Province of Buenos Aires; which is not associated with any institution or organi-
zation except the same Ministry, as it is the Ethics Committee of the said body, and evaluates
all projects developed by institutions of the Ministry.
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In the protocol of the present study, the Central Ethics Committee acts as an Institutional
Evaluation Committee in use of the powers provided for by Decree 3385/08 as a research proj-
ect, in which the Ministry of Health of the Province of Buenos Aires acts both as sponsor and
center.
The Central Committee established that this observational study had an adequate risk-ben-
efit ratio and requested the anonymization of data.
The administration of convalescent plasma required signed consent from each patient or
legal representative, according to CROCPD-BA regulations (Expedient 2919/2123/2020).
Results
During the study period, 3,529 patients with COVID-19 pneumonia were admitted to 215 hos-
pitals. Epidemiological data of the entire group and comparisons between survivors and non-
survivors are shown in Table 1. Briefly, this was a predominantly male population, aged 62±17
years, with arterial hypertension and diabetes as main comorbidities. With respect to disease
severity, 51.4% were admitted to the ward, 27.1% to the ICU without mechanical ventilation
need, and 21.7% to the ICU, with mechanical ventilation requirement (ICU-MV).
Twenty-eight-day mortality was 34.9% for the entire group; and respectively, for ward, ICU
and ICU-MV patients was 26.3%, 30.1% and 61.4%. Survivors were significantly younger, had
less comorbidities, lower admission to the ICU, and had received plasma more frequently.
Convalescent plasma was administered to 868 patients (24.6%) (Table 2). Compared to the
remaining 2,661, this group was composed of younger and predominantly male patients, with
higher prevalence of arterial hypertension, diabetes, and higher ICU admission. The rate of
mechanical ventilation use was similar in both groups.
Twenty-eight-day unadjusted mortality was lower in the entire group of patients receiving
convalescent plasma, compared to those who had not (25.5% vs. 38.0%; OR 0.59 [0.47–0.66],
Table 1. Characteristics of the entire group, and comparison between survivors and nonsurvivors.
All patients Survivors Nonsurvivors P value
n 3529 n 2298 (65.1%) n 1231 (34.9%)
Age (years) 62 ± 17 58 ± 17 69 ± 15 < 0.001
Gender (male) 2147 (60.8) 1419 (61.7) 718 (59.1) 0.130
Number of comorbidities P < 0.001
0 1409 (39.9) 1028 (44.7) 381 (31.0)
1 939 (26.6) 585 (25.5) 354 (28.8)
2 683 (19.4) 425 (18.5) 258 (21.0)
� 3 498 (14.1) 260 (11.3) 238 (19.3)
Mean of comorbidities 1.20 ± 1.21 1.09 ± 1.18 1.39 ± 1.23 < 0.001
Arterial hypertension 1256 (35.6) 720 (31.3) 536 (43.5) < 0.001
Diabetes 756 (21.4) 454 (19.8) 302 (24.5) 0.001
Preexistent cardiovascular disease 366 (10.4) 180 (7.8) 186 (15.1) <0.001
Chronic obstructive pulmonary disease 268 (7.6) 161(7.0) 107(8.7) 0.072
Immunodeficiency 79 (2.2) 46 (2.0) 33 (2.7) 0.194
Site of admission
General ward 1815 (57.4) 1337 (58.2) 478 (38.8) <0.001
Intensive Care Unit 957 (27.1) 669 (29.1) 288 (23.4) <0.001
Intensive care unit requiring mechanical ventilation 757 (21.7) 292 (12.7) 465 (37.8) <0.001
Administration of convalescent plasma 868 (24.6) 647 (28.2) 221 (18.0) <0.001
Length of ICU stay (days) 10 [5–19] 13 [6–24] 8 [4–14] <0.001
https://doi.org/10.1371/journal.pone.0250386.t001
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p<0.001). The effect of plasma was more evident in patients in the ward (28-day mortality of
14.0% vs. 29.9% in those not receiving plasma; OR 0.38 [0.28–0.52], p<0.001), and in the
ICU-MV patients (50.0% vs. 65.0%; OR 0.54 [0.38–0.75], p<0.001). In patients in the ICU
who did not require MV the administration of plasma had no effect on mortality (26.1% vs.
31.8%; OR 0.76 [0.56–1.03], p = 0.081) (S1 Table in S1 File).
Logistic regression analysis identified age, ICU admission with and without MV, diabetes
and preexistent cardiovascular disease as independent predictors of 28-day mortality, while
hypertension and COPD were not independent predictors. Convalescent plasma administra-
tion was associated with decreased mortality (Table 3).
Table 2. Characteristics of patients receiving and non-receiving convalescent plasma.
No Plasma Plasma P value
n 2661 (75.4%) n 868 (24.6%)
Age (years) 64 ± 17 56 ± 13 < 0.001
Gender (male) 1547 (58.1) 600 (69.1) < 0.001
Number of comorbidities P < 0.001
0 1128 (42.4) 281 (32.3)
1 660 (24.2) 279 (32.1)
2 495 (18.6) 188 (21.7)
� 3 378 (14.2) 120 (13.8)
Mean of comorbidities 1.11 ± 1.23 1.55 ± 1.06 < 0.001
Arterial hypertension 914 (34.3) 342 (39.4) 0.007
Diabetes 532 (20.0) 224 (25.8) < 0.001
Preexistent cardiovascular disease 282 (10.6) 84 (9.7) 0.440
Chronic obstructive pulmonary disease 201 (8.7) 67 (7.7) 0.873
Immunodeficiency 59 (2.2) 20 (2.3) 0.880
Site of admission
General ward 1409 (53) 406 (46.8) 0.002
Intensive Care Unit 677 (25.4) 280 (32.3) < 0.001
Intensive care unit requiring mechanical ventilation 575 (21.6) 182 (21.0) 0.690
28-day mortality 1010 (38.0) 221 (25.5) < 0.001
Length of ICU stay (days) 10 [4–17] 12 [7–18] <0.001
https://doi.org/10.1371/journal.pone.0250386.t002
Table 3. Independent predictors of 28-day mortality, as identifies with logistic regression.
Variables in the Equation B SE OR 95% C.I. P value
Admission to the ICU (vs. admission to the ward) 0.26 0.09 1.30 1.08–1.56 0.006
Admission to the ICU with MV requirement (vs. admission to the ward) 1.75 0.10 5.73 4.71–7.00 < 0.001
Preexistent cardiovascular disease (yes/no) 0.38 0.12 1.46 1.14–1.85 0.002
Diabetes (yes/no) 0.29 0.09 1.33 1.11–1.60 0.002
Age (per year) 0.045 0.003 1.05 1.04–1.05 < 0.001
Administration of convalescent plasma (yes/no) -0.31 0.10 0.73 0.60–0.89 0.002
Variables not in the Equation
Hypertension 0.179
COPD 0.449
Abbreviations. ICU (Intensive Care Unit); MV (mechanical ventilation).
https://doi.org/10.1371/journal.pone.0250386.t003
PLOS ONE Plasma and COVID-19 outcome
PLOS ONE | https://doi.org/10.1371/journal.pone.0250386 April 29, 2021 5 / 10
Discussion
The main finding of our study was that older age, diabetes and antecedents of cardiovascular
disease were independent risk factors for 28-day mortality for COVID-19 pneumonia, while
the administration of convalescent plasma acted as a protective factor. This effect was more
evident in less sick patients—those admitted to the general ward.
In this study, the global mortality of 34.6% was higher than the 21–28% shown in observational
studies [20–23] which can be ascribed to a different patient case-mix. The proportion of patients
admitted to the ICU was 42.6%, of which 21.6% required mechanical ventilation on admission.
These figures are notably higher than those reported by two studies from Spain (respectively for
each: n = 15,111 and 4,035, with ICU admission of 8.3% and 18%; and mortality of 21% and
28%); United States (n = 11,721, ICU admission of 19.9%, and mortality of 21.4%), and United
Kingdom (n = 20,133, ICU admission 16.8%, and mortality of 26%) [20–23].
The efficacy of convalescent plasma in COVID-19 has been subject to much debate, due to
the lack of a clinical trial with sufficient power to confirm it. For example, a study carried out
in Wuhan was prematurely terminated due to the end of the pandemic, although significant
clinical improvement was observed in patients with severe disease [10]. Likewise, a study from
The Netherlands was stopped because 79% of patients already had high titers of neutralizing
antibodies before receiving convalescent plasma [24]. A recent clinical trial from India which
excluded critically ill patients did not find any clinical benefit. However, these results might be
ascribed to the absence of neutralizing antibodies or to titers lower than 1:80 in 27% and 45%
of convalescent plasma units, respectively [25]. Moreover, 86% of patients in the plasma sub-
group had detectable neutralizing antibodies on enrollment; so it is uncertain if the interven-
tion would have been efficacious.
Conversely, two small clinical trials demonstrated a significant decrease in mortality: in a
study from Spain (n = 81) including severely ill patients, mortality in the convalescent plasma
subgroup was 0% vs. 9.3% in the control, and in an Iraqi study (n = 49), it was 4.8% vs. 28.5%,
respectively [26, 27].
Many observational studies support a probable efficacy of convalescent plasma. For exam-
ple, a case-control study from China (including 138 cases and 1,568 controls) reported 2.2%
mortality for the convalescent plasma subgroup, versus 4.1% for the control [28]. Furthermore,
in a case-control study from the US including non-ventilated patients, 14-day mortality was
12.8% in the subgroup that had received convalescent plasma, vs. 24.4% in the control [29].
Similar results were reported in a matched case-control study, also from the US (136 cases, 251
controls), which showed lower mortality in patients receiving early administration of conva-
lescent plasma with high titers of antibodies: 1.2% vs 8.9% [12]. Finally, the large case-series
from the Mayo Clinic (n = 35,322) showed a relative risk of 30-day mortality of 0.77 [0.63–
0.94] among patients transfused with plasma units of high antibody titers, compared to those
transfused with low titers [14].
Our study develops a different approach to this very relevant issue. We analyzed a cohort of
3,529 unselected, consecutive patients with COVID-19 pneumonia, of whom 868 received
convalescent plasma; its administration was evaluated as any other prognostic variable for
mortality. We observed an independent, favorable effect on survival. Although the nature of
our study was observational, it was carried out using a robust database composed of observa-
tions prospectively collected, within the framework of a pre-established government program.
Other independent predictors of mortality were age, diabetes and cardiovascular disease, simi-
lar to current literature on the topic [22, 30–33].
This effect of convalescent plasma was more pronounced in less severe patients—those
admitted to the ward, suggesting the importance of timely administration. Even though age
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>65 was one inclusion criterion for receiving convalescent plasma, surprisingly, those who
received it were, in fact, younger. We cannot discard selection bias of physicians prescribing a
seemingly promising therapy to patients with greater chances of responding to it. Nevertheless,
older age was an independent predictor of mortality, as expected [22, 33].
The main limitation of this study is the lack of randomized assignment of convalescent
plasma administration. A matching of cases receiving convalescent plasma with similar con-
trols could not be done because of the type of data recorded in the register. It is thus possible
that unmeasured confounders might have influenced the results, such as other risk factors or
treatments. Notwithstanding this, the retrospective cohort design has already been applied for
the analysis of the effect of convalescent plasma on COVID-19 [14]. Regarding possible differ-
ences in outcomes related to the adoption of specific therapies for COVID-19, the Ministry of
Health of the Province of Buenos Aires has issued recommendations for the treatment of
COVID-19, and encourages compliance with them. Since severity of illness on admission
could not be evaluated with an established score, hence misclassification of patients might
have occurred. The use of severity of illness on admission as a surrogate of acuity. However,
our approach has already been utilized [3]. It is possible that convalescent plasma might be
efficacious in particular patient subgroups. In this way, observational studies might help to
identify populations in which this therapy might be beneficial, such as in patients with less
severe disease but with high potential of clinical deterioration, or in those with short duration
of symptoms. The duration of symptoms before convalescent plasma administration was not
available in our cohort. Although a possible key determinant of convalescent plasma effect,
previous symptom duration is difficult to ascertain and might be subjected to recall bias. A
more detailed analysis of the clinical variables collected could not be done, because of the type
of data recorded in the register. Finally, the reason why assistant physicians chose not to
administer convalescent plasma to patients with COVID-19 pneumonia fulfilling the inclusion
criteria are unknown, but we speculate that some physicians might have felt uncomfortable
with prescribing an experimental treatment to their patients.
Conclusions
Our study suggests that the administration of convalescent plasma in COVID-19 pneumonia
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